SynBioBeta Speaker
Geoff Hamilton
Ansa Biotechnologies
Chief Business & CFO
Geoff Hamilton is the Chief Business and Chief Financial Officer of Ansa Biotechnologies, a leading provider of gene synthesis products powering the next era of medicines and engineered biology. Geoff has a 24 year career in the industry spanning life science tools, genomics, and therapeutics. Geoff has been a leader in developing and launching revolutionary technologies in next-generation sequencing and applying gene and cell engineering tools to develop breakthrough therapeutics. Prior to joining Ansa, Geoff was the cofounder and CEO of Stemson Therapeutics, a cell therapy company developing regenerative treatments for skin diseases and hair loss conditions. Prior to founding Stemson, he spent six years at Illumina where he held leadership positions in product commercialization, clinical marketing, sequencing application strategy, and product portfolio management. Before Illumina, Geoff spent a decade at Life Technologies, a leading provider of tools, reagents, and analytical instruments before it was acquired by ThermoFisher Scientific. At Life Tech, he held a number of finance, marketing, commercial, and acquisition leadership roles.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Geoff
This Year
•
-
Human Health
Stagnant No More: DNA Synthesis Innovation Brings Much-Needed Reliability to Biopharma
The synthetic DNA field has entered an era of rapid innovation that is giving biopharma scientists new options when deciding whether to build or buy long and complex DNA. Previously hard-to-source DNA constructs are now readily available with an unprecedented guarantee for on-time shipping, eliminating procurement delays and empowering researchers to push the boundaries of synthetic biology. In this session, leading scientists will discuss how these advances are expanding design possibilities, accelerating design–build–test–learn cycles, and paving the way for the next wave of precision biotherapeutics.
Get a Ticket
•
-
Human Health
Stagnant No More: DNA Synthesis Innovation Brings Much-Needed Reliability to Biopharma
The synthetic DNA field has entered an era of rapid innovation that is giving biopharma scientists new options when deciding whether to build or buy long and complex DNA. Previously hard-to-source DNA constructs are now readily available with an unprecedented guarantee for on-time shipping, eliminating procurement delays and empowering researchers to push the boundaries of synthetic biology. In this session, leading scientists will discuss how these advances are expanding design possibilities, accelerating design–build–test–learn cycles, and paving the way for the next wave of precision biotherapeutics.
Get a Ticket
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
